Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Singulex
Information provided by (Responsible Party):
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT00455403
First received: March 30, 2007
Last updated: December 24, 2013
Last verified: December 2013

March 30, 2007
December 24, 2013
April 2006
January 2014   (final data collection date for primary outcome measure)
Carotid intima-media thickness [ Time Frame: Measured at baseline and year 1 ] [ Designated as safety issue: No ]
  • Carotid intima-media thickness
  • Plaque area (both measured at Months 12 and 24)
Complete list of historical versions of study NCT00455403 on ClinicalTrials.gov Archive Site
Not Provided
  • Reduction in blood pressure
  • Weight and waist circumference
  • Glucose levels
  • Insulin resistance
  • Change in lipid levels
  • Monocyte activation (all measured at Months 12 and 24)
Not Provided
Not Provided
 
Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome- Aim 3

Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes. The purpose of this study is to evaluate the long-term effectiveness of chloroquine, a protein-activation medication, at reducing the progression of atherosclerosis in patients with the metabolic syndrome.

Sub-study: Vascular endothelial growth factor(VEGF)and Cardiometabolic Risk, The purpose is to determine if the association of VEGF with atherosclerosis indicates that it should be a marker of the disorder.

Metabolic syndrome is one of the most common disorders in industrialized countries. It consists of abnormal serum lipids, glucose intolerance, elevated blood pressure, and central obesity in the setting of insulin resistance. The syndrome substantially increases the risk of developing diabetes and vascular disease, but there is no clear unifying approach to treat this disorder. In animals, activation of the protein ataxia telangiectasia mutated (ATM) using the antimalarial drug chloroquine improves features of metabolic syndrome and decreases atherosclerosis, a build-up of fatty plaque within arteries. The purpose of this study is to examine the effect of long-term treatment with low doses of chloroquine on atherosclerosis in people with metabolic syndrome.

At a baseline study visit, participants will undergo an ultrasound of the neck to evaluate carotid artery intima-media thickness (IMT) and MRI to evaluate plaque composition. In addition, blood will be collected for laboratory testing and blood pressure will be measured. Participants will then be randomly assigned to receive either placebo or chloroquine. Study visits will occur every 3 months for 1 year. At each visit, blood pressure will be measured and blood will be collected. At Months 6 and 12, a repeat ultrasound will be performed. At month 12 a repeat carotid MRI is performed. Participants will attend one follow-up visit at Month 24 and will undergo a final ultrasound.

Sub-Study: VEGF and Cardiometabolic Risk, (This is an observational, case-study of existing baseline plasma and carotid intimal-medial thickness measurements) VEGF is also closely linked to vascular disease. From cell culture and animal models it is known that VEGF is increased in atherosclerotic lesions. It is controversial whether that relationship is causative or reparative. Both pro- and anti-VEGF therapies have been proposed for atherosclerosis. However, the association of VEGF with atherosclerosis indicates that it should be a marker of the disorder, which is the hypothesis we wish to test. No previous studies of circulating VEGF have been published.

Other markers may be related to vascular disease or VEGF in this dataset. Tumor necrosis factor (TNF)-alpha results in increased expression of VEGF and may be correlated positively with VEGF. By Erenna Technology testing, cardiac troponin I can be measured at levels much lower than current clinical assays and is expected to be elevated in ischemia but not necessarily in the stable vascular disease anticipated in our subjects. High sensitivity C-reactive protein (hsCRP)has been proposed as a marker for vascular disease that merits drug treatment in its own right and may also be correlated with VEGF and vascular disease. However, currently the relationship between hsCRP and vascular disease is not completely clear.

For this preliminary VEGF study observational data from the baseline only will be studied. Baseline testing includes carotid artery intimal-medial thickness, carotid MRI, lipid panel, complete blood count, comprehensive metabolic chemistry panel, Thyroid-stimulating hormone (TSH) and glucose tolerance test with plasma insulin and glucose responses. Plasma collected at baseline (approximately 1 ml) will be transferred to Singulex on dry ice. Samples will be coded but will not contain patient identifiers. Erenna Technology assays will be done for VEGF-A, cardiac troponin I,TNF-alpha, interleukin-6, interleukin-17A, and other cytokines at Singulex. This method utilizes single-photon counting of visible light to improve assay sensitivity. Separately, Washington University's Core Lab for Clinical Studies (CLCS) will determine hsCRP.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Metabolic Syndrome X
  • Overweight
  • Hypertension
  • Dyslipidemias
  • Prediabetic State
  • Drug: Chloroquine
    One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24
    Other Name: Arlen
  • Drug: Placebo Comparator
    Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24
    Other Name: placebo
  • Experimental: 1
    Participants will receive 80 mg of chloroquine on a daily basis.
    Intervention: Drug: Chloroquine
  • Placebo Comparator: 2
    Participants will receive a placebo comparator tablet on a daily basis.
    Intervention: Drug: Placebo Comparator
Razani B, Feng C, Semenkovich CF. p53 is required for chloroquine-induced atheroprotection but not insulin sensitization. J Lipid Res. 2010 Jul;51(7):1738-46. doi: 10.1194/jlr.M003681. Epub 2010 Mar 5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
150
January 2014
January 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of metabolic syndrome, as determined by at least three of the following five criteria:

    1. Elevated fasting triglyceride level greater than 150 mg/dL
    2. Low HDL cholesterol levels: less than 50 mg/dL for women and less than 40 mg/dL for men
    3. Hypertension (greater than or equal to 130/85 mm Hg and less than or equal to 160/100 mm Hg) untreated; or hypertension controlled (less than or equal to 150/90 mm Hg) on a stable medication regimen for 4 weeks prior to baseline visit.
    4. Increased waist circumference: greater than 35 inches in women and greater than 40 inches in men
    5. Elevated fasting glucose level greater than or equal to 100 mg/dL and less than or equal to 126 mg/dL
  • Willing to use acceptable form of birth control
  • Subjects may be on a stable doses of a statin drug for at least 3 months
  • Subjects may be on a stable doses of L-thyroxine for at least 3 months

Exclusion Criteria:

  • Prior travel treatment with chloroquine or hydroxychloroquine as follows:

    1. Any exposure in the past 2 years
    2. More than 30 days of therapy if exposure was between 2 and 5 years ago
    3. More than 90 days of therapy if exposure was between 5 and 10 years ago
    4. More than 6 months of therapy if exposure was 10 to 20 years ago
    5. More than 1 year of therapy if exposure was 20 to 30 years ago
    6. No limit if last exposure was more than 30 years ago (e.g., during the Vietnam conflict)
  • Morbid obesity (body mass index [BMI] greater than 45)
  • Coronary artery disease or other vascular disease
  • History of stroke
  • Significant kidney disease (estimated glomerular filtration rate (eGFR)less than 60 mL/min/1.73 m2)
  • Diabetes
  • Seizure disorder
  • History of psoriasis
  • Blood disorders, including anemia (i.e., hemoglobin levels less than 13 g/dL in men and less than 12 g/dL in women)
  • Current malignancy or active treatment for recurrence prevention, example tamoxifen. Cancer considered to be cured, either as a result of surgery or other treatment is not exclusionary.
  • Asthma requiring daily beta agonist therapy or intermittent oral steroids is exclusionary. Inhaled steroids are acceptable. Obstructive sleep apnea will be allowed if Continuous Positive Airway Pressure (CPAP) or other therapy has been stable for 6 months. Other active respiratory diseases are excluded.
  • Liver disease, or liver function test results greater than twice the normal value
  • Active infection, including HIV
  • Serious illness requiring ongoing medical care or medication
  • Treatment with atypical anti-psychotic medication. Treatment with any other medication for psychiatric illness, unless on a stable dose for 6 weeks prior to enrollment. Patients with unstable psychiatric disorders are excluded per the decision of the study MD regardless of medication history.
  • Receiving any of the following lipid lowering medications: niacin, fibrates, or fish oils greater than 1 gram
  • Uncontrolled hypertension (blood pressure greater than or equal to 150/90) at baseline visit.
  • Need for daily over the counter medications, or currently taking cimetidine or greater than 1000 IU vitamin E daily and unwilling to reduce or discontinue the use of vitamin E or discontinue cimetidine for the duration of the study. Patients taking greater than 1000 IU of vitamin E should reduce the dose 30 days prior to randomization.
  • Pregnant, breastfeeding, or intending to become pregnant
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • Retinal disease
  • Auditory disease or hearing loss; patients with total, irreversible hearing loss can be enrolled
  • Participation in another clinical trial within past 30 days prior to screening and 60 days prior to randomization. Questionnaire or observational studies are not exclusionary.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00455403
482, P50HL083762
Yes
Washington University School of Medicine
Washington University School of Medicine
  • National Heart, Lung, and Blood Institute (NHLBI)
  • Singulex
Principal Investigator: Clay F. Semenkovich, MD Washington University School of Medicine
Washington University School of Medicine
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP